FDA to examine 7 popular weight-loss peptides

The FDA is reviewing seven unapproved peptide substances, widely available through clinics and online sellers, to potentially include them on the 503A Bulks List for compounded drugs. Experts, including Dr. Alex Tatem, highlight their promising safety profiles based on real-world data, despite limited formal clinical trials. The agency's advisory committee will decide whether to recommend approval, with the decision affecting future access for patients seeking treatments for conditions like wound healing, inflammation, and neurological issues.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل